Fernando J. Muzzio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Fernando J. Muzzio


Fernando J. Muzzio, PhD, is a Pharmtech editorial advisory board (EAB) member

Fernando J. Muzzio, PhD
Director, NSF Engineering Research Center on Structured Organic Particulate Systems, Department of
Chemical and Biochemical
Engineering,
Rutgers University

Fernando J. Muzzio is a professor in the Department of Chemical and Biochemical Engineering at Rutgers University. He currently serves as the director of the NSF Engineering Research Center on Structured Organic Particulate Systems, the director of the NSF-NIH Nanopharmaceutical Engineering IGERT training program, the co-chair of the technology subcommittee for the National Institute for Pharmaceutical Technology and Education. He is a member of the editorial boards of Pharmaceutical Technology and the Journal for Pharmaceutical Innovation.

Muzzio has published more than 140 peer-reviewed papers, written eight book chapters, presented numerous papers at major technical meetings, and holds six patents. He has been invited to present at numerous academic, industry, and federal seminars.

He received his PhD from the University of Massachusetts at Amherst in chemical engineering in 1991. His thesis was titled: "Non-Linearity, Chaos, and Self-Similarity: Effects of Mixing, Aggregation, Reaction, and Breakup on Structure Formation." He holds a BS in chemical engineering from the University of Mar del Plata, Argentina. 

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here